171 related articles for article (PubMed ID: 21150591)
41. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.
Nichols BE; Sigaloff KC; Kityo C; Hamers RL; Baltussen R; Bertagnolio S; Jordan MR; Hallett TB; Boucher CA; de Wit TF; van de Vijver DA
J Int AIDS Soc; 2014; 17(1):19164. PubMed ID: 25491351
[TBL] [Abstract][Full Text] [Related]
42. Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.
Phillips AN; Cambiano V; Nakagawa F; Bansi-Matharu L; Sow PS; Ehrenkranz P; Ford D; Mugurungi O; Apollo T; Murungu J; Bangsberg DR; Revill P
PLoS One; 2016; 11(12):e0167654. PubMed ID: 27977702
[TBL] [Abstract][Full Text] [Related]
43. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M
J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471
[TBL] [Abstract][Full Text] [Related]
44. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.
Huerta García G; Mata-Marín JA; Domínguez-Hermosillo JC; Chavez-García M; Banda-Lara MI; Nuñez-Rodríguez N; Cruz-Herrera JE; Sandoval-Ramírez JL; Villagómez-Ruiz A; Manjarrez-Tellez B; Gaytan-Martínez JE
J Infect Dev Ctries; 2016 Jun; 10(6):605-11. PubMed ID: 27367009
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic drug monitoring of antiretroviral therapy.
Rakhmanina NY; van den Anker JN; Soldin SJ
AIDS Patient Care STDS; 2004 Jan; 18(1):7-14. PubMed ID: 15006189
[TBL] [Abstract][Full Text] [Related]
47. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
48. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
Kumarasamy N; Krishnan S
Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
[TBL] [Abstract][Full Text] [Related]
49. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.
Colebunders R; Moses KR; Laurence J; Shihab HM; Semitala F; Lutwama F; Bakeera-Kitaka S; Lynen L; Spacek L; Reynolds SJ; Quinn TC; Viner B; Mayanja-Kizza H
Lancet Infect Dis; 2006 Jan; 6(1):53-9. PubMed ID: 16377535
[TBL] [Abstract][Full Text] [Related]
50. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Suter F
AIDS; 2004 Feb; 18(3):439-46. PubMed ID: 15090796
[TBL] [Abstract][Full Text] [Related]
51. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Rewari BB; Bachani D; Rajasekaran S; Deshpande A; Chan PL; Srikantiah P
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):610-4. PubMed ID: 20890211
[TBL] [Abstract][Full Text] [Related]
52. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?
Braithwaite RS; Nucifora KA; Yiannoutsos CT; Musick B; Kimaiyo S; Diero L; Bacon MC; Wools-Kaloustian K
J Int AIDS Soc; 2011 Jul; 14():38. PubMed ID: 21801434
[TBL] [Abstract][Full Text] [Related]
53. A targeted approach for routine viral load monitoring in Malawian adults on antiretroviral therapy.
Mungwira RG; Divala TH; Nyirenda OM; Kanjala M; Muwalo F; Mkandawire FA; Choko A; Taylor TE; Mallewa J; van Oosterhout JJ; Laufer MK; Laurens MB
Trop Med Int Health; 2018 May; 23(5):526-532. PubMed ID: 29505108
[TBL] [Abstract][Full Text] [Related]
54. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
55. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
56. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
57. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
[TBL] [Abstract][Full Text] [Related]
58. HIV treatment and care in resource-constrained environments: challenges for the next decade.
Eholié SP; Aoussi FE; Ouattara IS; Bissagnéné E; Anglaret X
J Int AIDS Soc; 2012 Aug; 15(2):17334. PubMed ID: 22944479
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
60. Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.
Gerlach J; Sequeira M; Alvarado V; Cerpas C; Balmaseda A; Gonzalez A; de Los Santos T; Levin CE; Amador JJ; Domingo GJ
J Int AIDS Soc; 2010 Nov; 13():43. PubMed ID: 21054866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
